Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
AIDS and Behavior
Published in: AIDS and Behavior 4/2017

01-04-2017 | Original Paper

Erectile Dysfunction Medication Prescription and Condomless Intercourse in HIV-Infected Men Who have Sex with Men in the United States

Authors: Xia Lin, Christine L. Mattson, Mark Freedman, Jacek Skarbinski, For the Medical Monitoring Project

Published in: AIDS and Behavior | Issue 4/2017

Login to get access

Abstract

Using nationally representative data, we assessed the prevalence of erectile dysfunction medication (EDM) prescription, and its association with insertive condomless anal intercourse (CAI) with an HIV-serodiscordant partner among sexually-active HIV-infected men who have sex with men (MSM) receiving medical care in the United States. Overall, 14 % (95 % CI 12–16) were prescribed EDM and 21 % (95 % CI 19–23) engaged in serodiscordant CAI. MSM who were prescribed EDM were more likely to engage in insertive CAI with a serodiscordant casual partner than those not prescribed EDM after adjusting for illicit drug use before or during sex (adjusted prevalence ratio = 1.38; 95 % CI 1.01–1.88). We found no association with main partners. Only 40 % (95 % CI 36–44) of MSM prescribed EDM received risk-reduction counseling from healthcare professionals. Risk-reduction counseling should be provided at least annually to all HIV-infected persons as recommended, especially at the time of EDM prescription.
Literature
1.
2.
Samji H, Cescon A, Hogg RS, Modur SP, Althoff KN, Buchacz K, et al. Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada. PLoS ONE. 2013;8:e81355.CrossRefPubMedPubMedCentral
3.
Önen NF, Overton ET, Seyfried W, Stumm ER, Snell M, Mondy K, et al. Aging and HIV Infection: a comparison between older HIV-infected persons and the general population. HIV Clin Trials. 2010;11:100–9.CrossRefPubMed
4.
Buchacz K, Baker RK, Palella FJ Jr, Shaw L, Patel P, Lichtenstein KA, et al. Disparities in prevalence of key chronic diseases by gender and race/ethnicity among antiretroviral-treated HIV-infected adults in the US. Antivir Ther. 2013;18(1):65–75.CrossRefPubMed
5.
Lallemand F, Salhi Y, Linard F, Giami A, Rozenbaum W. Sexual dysfunction in 156 ambulatory HIV-infected men receiving highly active antiretroviral therapy combinations with and without protease inhibitors. J Acquir Immune Defic Syndr. 2002;30:187–90.CrossRefPubMed
6.
Cove J, Petrak J. Factors associated with sexual problems in HIV-positive gay men. Int J STD AIDS. 2004;15:732–6.CrossRefPubMed
7.
Crum-Cianflone NF, Bavaro M, Hale B, Amling C, Truett A, Brandt C, et al. Erectile dysfunction and hypogonadism among men with HIV. AIDS Patient Care STDS. 2007;21:9–19.CrossRefPubMed
8.
Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol. 1994;151:54–61.PubMed
9.
Selvin E, Burnett AL, Platz EA. Prevalence and risk factors for erectile dysfunction in the US. Am J Med. 2007;120:151–7.CrossRefPubMed
10.
Foster SA, Annunziata K, Shortridge EF, Freedman D, Viktrup L. Erectile dysfunction with or without coexisting benign prostatic hyperplasia in the general US population: analysis of US National Health and Wellness Survey. Curr Med Res Opin. 2013;29:1709–17.CrossRefPubMed
11.
Asboe D, Catalan J, Mandalia S, Dedes N, Florence E, Schrooten W, et al. Sexual dysfunction in HIV-positive men is multi-factorial: a study of prevalence and associated factors. AIDS Care. 2007;19:955–65.CrossRefPubMed
12.
Lamba H, Goldmeier D, Mackie NE, Scullard G. Antiretroviral therapy is associated with sexual dysfunction and with increased serum oestradiol levels in men. Int J STD AIDS. 2004;15:234–7.CrossRefPubMed
13.
Ende AR, Lo Re V 3rd, DiNubile MJ, Mounzer K. Erectile dysfunction in an urban HIV-positive population. AIDS Patient Care STDS. 2006;20:75–8.CrossRefPubMed
14.
Perez I, Moreno T, Navarro F, Santos J, Palacios R. Prevalence and factors associated with erectile dysfunction in a cohort of HIV-infected patients. Int J STD AIDS. 2013;24:712–5.CrossRefPubMed
15.
Santi D, Brigante G, Zona S, Guaraldi G, Rochira V. Male sexual dysfunction and HIV—a clinical perspective. Nat Rev Urol. 2014;11:99–109.CrossRefPubMed
16.
Crum NF, Furtek KJ, Olson PE, Amling CL, Wallace MR. A review of hypogonadism and erectile dysfunction among HIV-infected men during the pre- and post-HAART eras: diagnosis, pathogenesis, and management. AIDS Patient Care STDS. 2005;19:655–71.CrossRefPubMed
17.
Colson AE, Keller MJ, Sax PE, Pettus PT, Platt R, Choo PW. Male sexual dysfunction associated with antiretroviral therapy. J Acquir Immune Defic Syndr. 2002;30:27–32.CrossRefPubMed
18.
Shaeer O. The Global Online Sexuality Survey (GOSS): the United States of America in 2011 chapter II: phosphodiesterase inhibitors utilization among English speakers. J Sex Med. 2013;10:532–40.CrossRefPubMed
19.
Pantalone DW, Bimbi DS, Parsons JT. Motivations for the recreational use of erectile enhancing medications in urban gay and bisexual men. Sex Transm Infect. 2008;84:458–62.CrossRefPubMedPubMedCentral
20.
Mansergh G, Shouse RL, Marks G, Guzman R, Rader M, Buchbinder S, et al. Methamphetamine and sildenafil (Viagra) use are linked to unprotected receptive and insertive anal sex, respectively, in a sample of men who have sex with men. Sex Transm Infect. 2006;2:131–4.CrossRef
21.
Nettles CD, Benotsch EG, Uban KA. Sexual risk behaviors among men who have sex with men using erectile dysfunction medications. AIDS Patient Care STDS. 2009;23:1017–23.CrossRefPubMed
22.
Hirshfield S, Remien RH, Humberstone M, Walavalkar I, Chiasson MA. Substance use and high-risk sex among men who have sex with men: a national online study in the USA. AIDS Care. 2004;16:1036–47.CrossRefPubMed
23.
Patel P, Borkowf CB, Brooks JT, Lasry A, Lansky A, Mermin J. Estimating per-act HIV transmission risk: a systematic review. AIDS. 2014;28:1509–19.CrossRefPubMed
24.
Woolf-King SE, Rice TM, Truong HM, Woods WJ, Jerome RC, Carrico AW. Substance use and HIV risk behavior among men who have sex with men: the role of sexual compulsivity. J Urban Health. 2013;90:948–52.CrossRefPubMedPubMedCentral
25.
Spindler HH, Scheer S, Chen SY, Klausner JD, Katz MH, Valleroy LA, et al. Viagra, methamphetamine, and HIV risk: results from a probability sample of MSM, San Francisco. Sex Transm Dis. 2007;34:586–91.PubMed
26.
Ostrow DG, Plankey MW, Cox C, Li X, Shoptaw S, Jacobson LP, et al. Specific sex drug combinations contribute to the majority of recent HIV seroconversions among MSM in the MACS. J Acquir Immune Defic Syndr. 2009;51:349–55.CrossRefPubMedPubMedCentral
27.
Prestage G, Jin F, Kippax S, Zablotska I, Imrie J, Grulich A. Use of illicit drugs and erectile dysfunction medications and subsequent HIV infection among gay men in Sydney, Australia. J Sex Med. 2009;6:2311–20.CrossRefPubMed
28.
Kim AA, Kent CK, Klausner JD. Increased risk of HIV and sexually transmitted disease transmission among gay or bisexual men who use Viagra, San Francisco 2000–2001. AIDS. 2002;16:1425–8.CrossRefPubMed
29.
Frankel MR, McNaghten A, Shapiro MF, Sullivan PS, Berry SH, Johnson CH, et al. A probability sample for monitoring the HIV-infected population in care in the U.S. and in selected states. Open AIDS J 2012; 6:67–76.
30.
Blair JM, Fagan JL, Frazier EL, Do A, Bradley H, Valverde EE, et al. Behavioral and clinical characteristics of persons receiving medical care for HIV infection—Medical Monitoring Project, United States, 2009. MMWR Surveill Summ. 2014;63(Suppl 5):1–22.
31.
32.
33.
Heeringa SG, West BT, Berglund PA. Applied survey data analysis. London: Chapman and Hall; 2010.CrossRef
34.
Sarndal C-E, Lundstrom S. Estimation in surveys with non-response. Chichester: Wiley; 2005.CrossRef
35.
36.
37.
Kroenke K, Strine TW, Spitzer RL, Williams JB, Berry JT, Mokdad AH. The PHQ-8 as a measure of current depression in the general population. J Affect Disord. 2009;114:163–73.CrossRefPubMed
38.
SAS Institute Inc. Base SAS 9.3 utilities; reference. Cary, NC: SAS Institute Inc; 2011.
39.
SUDAAN 10.0.1. Research Triangle Park, NC: RTI International; 2009.
40.
Purcell DW, Wolitski RJ, Hoff CC, Parsons JT, Woods WJ, Halkitis PN. Predictors of the use of viagra, testosterone, and antidepressants among HIV-seropositive gay and bisexual men. AIDS. 2005;19(Suppl 1):S57–66.CrossRefPubMed
41.
Chu PL, McFarland W, Gibson S, Weide D, Henne J, Miller P, et al. Viagra use in a community-recruited sample of men who have sex with men, San Francisco. J Acquir Immune Defic Syndr. 2003;33:191–3.CrossRefPubMed
42.
Swearingen SG, Klausner JD. Sildenafil use, sexual risk behavior, and risk for sexually transmitted diseases, including HIV infection. Am J Med. 2005;118:571–7.CrossRefPubMed
43.
Moreau-Gruet F, Jeannin A, Dubois-Arber F, Spencer B. Management of the risk of HIV infection in male homosexual couples. AIDS. 2001;15(8):1025–35.CrossRefPubMed
44.
McLean J, Boulton M, Brookes M, Lakhani D, Fitzpatrick R, Dawson J, et al. Regular partners and risky behaviour: why do gay men have unprotected intercourse? AIDS Care. 1994;6(3):331–41.CrossRefPubMed
45.
Sullivan PS, Salazar L, Buchbinder S, Sanchez TH. Estimating the proportion of HIV transmissions from main sex partners among men who have sex with men in five US cities. AIDS. 2009;23(9):1153–62.CrossRefPubMed
46.
Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365:493–505.CrossRefPubMedPubMedCentral
47.
Gardner LI, Marks G, O’Daniels CM, Wilson TE, Golin C, Wright J, et al. Implementation and evaluation of a clinic-based behavioral intervention: positive steps for patients with HIV. AIDS Patient Care STDS. 2008;22:627–35.CrossRefPubMed
48.
Centers for Disease Control and Prevention, the Health Resources and Services Administration, the National Institutes of Health, American Academy of HIV Medicine, Association of Nurses in AIDS Care, International Association of Providers of AIDS Care, National Minority AIDS Council, Urban Coalition for HIV/AIDS Prevention Services. Recommendations for HIV Prevention with Adults and Adolescents with HIV in the United States, 2014; http://​stacks.​cdc.​gov/​view/​cdc/​26062. Published in 2014. Accessed January 2016.
49.
Centers for Disease Control and Prevention, Health Resources and Services Administration, National Institutes of Health, American Academy of HIV Medicine, Association of Nurses in AIDS Care, International Association of Providers of AIDS Care, National Minority AIDS Council, and Urban Coalition for HIV/AIDS Prevention Services. Recommendations for HIV Prevention with Adults and Adolescents with HIV in the United States, 2014: Summary for Clinical Providers. http://​stacks.​cdc.​gov/​view/​cdc/​26063. Published in 2014. Accessed January 2016.
50.
Metadata
Title
Erectile Dysfunction Medication Prescription and Condomless Intercourse in HIV-Infected Men Who have Sex with Men in the United States
Authors
Xia Lin
Christine L. Mattson
Mark Freedman
Jacek Skarbinski
For the Medical Monitoring Project
Publication date
01-04-2017
Publisher
Springer US
Published in
AIDS and Behavior / Issue 4/2017
Print ISSN: 1090-7165
Electronic ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-016-1552-1

Other articles of this Issue 4/2017

AIDS and Behavior 4/2017 Go to the issue

Original Paper

The Role of Internalized Stigma in the Disclosure of Injecting Drug Use Among People Who Inject Drugs and Self-Report as HIV-Positive in Kohtla-Järve, Estonia

Original Article

Gender, Transience, Network Partnerships and Risky Sexual Practices Among Young Persons who Inject Drugs

Brief Report

Correlates of Double Risk of HIV Acquisition and Transmission Among Women who Inject Drugs in St. Petersburg, Russia

Original Paper

Retention, Antiretroviral Therapy Use and Viral Suppression by History of Injection Drug Use Among HIV-Infected Patients in an Urban HIV Clinical Cohort

Original Paper

Primary Care Physicians’ Willingness to Prescribe HIV Pre-exposure Prophylaxis for People who Inject Drugs

Editorial

Pence, Putin, Mbeki and Their HIV/AIDS-Related Crimes Against Humanity: Call for Social Justice and Behavioral Science Advocacy
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits